References:

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals: Pihl, A. et al., Nature Scientific Reports volume 8, Article number: 17505 (2018) [Open Access]

Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model: Camilly P. Pires de Mello et al.; Antimicrob Agents Chemother 2018 62 [abstract]

Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system: Pires de Mello, C.P.; European Journal of Pharmaceutical Sciences 111 (2018) 443-449 [open access]

Antiviral Effects of Clinically-Relevant Interferon-alpha and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM): Pires de Mello, C.P. et al; Viruses 2018, 10, 317 [open access]

Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor: Tapia, F. et al.; Vaccine 2014 Feb 12;32(8):1003-11 [Open Access]

Considerations in Scale-Up of Viral Vaccine Production: William G. Whitford and Alain Fairbank; BioProcess International 2011 September [PDF]

Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model: Brown, A. et al.; Antimicrob. Agents Chemother. 2011 55 (4) 1747-1753[open access]

Antiviral pharmacodynamics in hollow fibre Bioreactors: McSharry, J. et al.; Antiviral Chemistry & Chemotherapy 2011; 21:183–192 [open access]

A Hollow fiber bioreactor for expanding HIV-1 in human lymphocytes used in preparing an inactivated vaccine candidate: Leong M, Bobbitt W, Vyas G, Biologicals, 2007 35 (4):227-233.

Advanced methods of adenovirus vector production for human gene therapy: roller
bottles, microcarriers, and hollow fibers: T. Isayeva, et al.; BioProcessing Journal 2003 75-81 [PDF]